More recently, a phase II clinical trial evaluating a selective JAK1/2 inhibitor in patients with metastatic triple-negative breast cancer (tumors demonstrating p-STAT3 expression) also demonstrated limited clinical efficacy [32]. Here, JAK1 is linked to triple-negative breast carcinoma.